Biontech Se Drn Stock Current Ratio

B1NT34 Stock  BRL 33.17  0.25  0.75%   
BIONTECH SE DRN fundamentals help investors to digest information that contributes to BIONTECH's financial success or failures. It also enables traders to predict the movement of BIONTECH Stock. The fundamental analysis module provides a way to measure BIONTECH's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to BIONTECH stock.
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

BIONTECH SE DRN Company Current Ratio Analysis

BIONTECH's Current Ratio is calculated by dividing the Current Assets of a company by its Current Liabilities. It measures whether or not a company has enough cash or liquid assets to pay its current liability over the next fiscal year. The ratio is regarded as a test of liquidity for a company.

Current Ratio

 = 

Current Asset

Current Liabilities

More About Current Ratio | All Equity Analysis
Typically, short-term creditors will prefer a high current ratio because it reduces their overall risk. However, investors may prefer a lower current ratio since they are more concerned about growing the business using assets of the company. Acceptable current ratios may vary from one sector to another, but the generally accepted benchmark is to have current assets at least as twice as current liabilities (i.e., Current Ration of 2 to 1).
Competition

In accordance with the recently published financial statements, BIONTECH SE DRN has a Current Ratio of 0.0 times. This is 100.0% lower than that of the Healthcare sector and 100.0% lower than that of the Biotechnology industry. The current ratio for all Brazil stocks is 100.0% higher than that of the company.

BIONTECH Current Ratio Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses BIONTECH's direct or indirect competition against its Current Ratio to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of BIONTECH could also be used in its relative valuation, which is a method of valuing BIONTECH by comparing valuation metrics of similar companies.
BIONTECH is currently under evaluation in current ratio category among its peers.

BIONTECH Fundamentals

About BIONTECH Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze BIONTECH SE DRN's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of BIONTECH using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of BIONTECH SE DRN based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Other Information on Investing in BIONTECH Stock

BIONTECH financial ratios help investors to determine whether BIONTECH Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in BIONTECH with respect to the benefits of owning BIONTECH security.